PB2679: MIXED-METHOD, CROSS-SECTIONAL SURVEY TO DESCRIBE FEELINGS, PERCEPTION, AND EXPERIENCE OF MULTIPLE MYELOMA PATIENTS WHO SWITCHED FROM INTRAVENOUS DARATUMUMAB TO THE SUBCUTANEOUS FORMULATION IN EUROPE

• Valeria Magarotto,
• Julien Thevenon,
• Kate Morgan,
• Silene Ten Seldam,
• Wafae Iraqi,
• Xavier Guillaume,
• Dahbia Horchi,
• Bleuenn Rault,
• Traugott Ludwig Gruppe

Affiliations

Valeria Magarotto

1 MD, Janssen-Cilag, Cologno Monzese MI, Italy

Julien Thevenon

2 Janssen Pharmaceuticals, Medical Affairs, Issy-les-Moulineaux, France

Kate Morgan

3 Myeloma Patients Europe, Brussels, Belgium

Silene Ten Seldam

3 Myeloma Patients Europe, Brussels, Belgium

Wafae Iraqi

4 Janssen Pharmaceuticals, Patient Engagement, Issy-les-Moulineaux, France

Xavier Guillaume

5 Cerner Enviza, France

Dahbia Horchi

5 Cerner Enviza, France

Bleuenn Rault

5 Cerner Enviza, France

Traugott Ludwig Gruppe

6 MD, Janssen-Cilag, Neuss, Germany